Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy

NCT03419572 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT03419572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03419572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy
Lead sponsor
Ipsen
Phase
Observational
Overall status
Completed
Start date
April 24, 2018
Completion date
May 19, 2022
Enrollment
689 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma